Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av neuropsykiatriska tillstånd
14 févr. 2022 02h00 HE
|
Nexstim Oyj
Företagsmeddelande, insiderinformation, Helsingfors 14.2.2022 kl. 9.00 (EET) Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av...
Nexstim har kommit överens om en strategisk investering i en Management Services-organisation för en Kalifornien-baserad klinik som tillhandahåller behandlingar för depressionspatienter
22 nov. 2021 02h00 HE
|
Nexstim Oyj
Företagsmeddelande, insiderinformation, Helsingfors, 22.11.2021 kl. 9.00 (EET) Nexstim har kommit överens om en strategisk investering i en Management Services-organisation för en Kalifornien-baserad...
Nexstim on sopinut strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön
22 nov. 2021 02h00 HE
|
Nexstim Oyj
Yhtiötiedote, sisäpiiritieto, Helsinki, 22.11.2021 klo 9.00 (EET) Nexstim on sopinut strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön ...
Nexstim Agrees on a Strategic Investment into a Management Services Organisation of a California Based Clinic Providing Treatments for Depression Patients
22 nov. 2021 02h00 HE
|
Nexstim Oyj
Company Announcement, Inside information, Helsinki, 22.11.2021 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organisation of a California Based Clinic Providing...
Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
23 août 2021 06h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
01 déc. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months Rapid and substantial improvement in...
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
04 nov. 2020 07h03 HE
|
Axsome Therapeutics, Inc.
Collaboration provides Axsome access to new digital technologies developed by Veeva NEW YORK and PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder
14 sept. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001) Clinical...
Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program
10 août 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Enrollment complete in the COMET Phase 3 long-term safety trial of AXS-05 in MDD; NDA filing on track for 4Q 2020 Results from three Phase 2 open-label efficacy trials of AXS-05 in TRD,...
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder
13 juil. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NDA submission on track for 4Q 2020 NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...